IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation

NCT01931865 ↗

Phase 2 Terminated 12 enrolled Yale University Merz North America, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to investigate the safety and effectiveness of botulinum toxin A (Xeomin) ® injections in patients who suffer from focal pain in areas of radiation and/or surgery as a result of cancer treatment. Our hypothesis is that injection of incobotulinum toxin A into an area of local pain, at or around the area of a post-surgical/post radiation scar, relieves the focal cancer pain.

Timeline

Start: 2012-09
Primary completion: 2015-06
Completion: 2015-07

Outcome

Outcome not reported

Stopped (Enrollment): “lost the recruiting source- no recruitment for the past 18months, PI moving”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Botulinum toxin type A	Protein / enzyme biologic	100 iu	Intramuscular

Indications

No indication recorded.